Improvements in survival among cancer patients have revealed the clinical impact of
cardiotoxicity on both cardiovascular and hematological and oncological outcomes …

Aim: To compare real-world effectiveness/safety of non-vitamin K antagonist oral
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …

Background and objectives: Anticoagulants are thought to increase the risks of traumatic
intracranial injury and poor clinical outcomes after blunt head trauma. The safety of using …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

To assess the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with
atrial fibrillation (AF) after the use of rivaroxaban or warfarin. To investigate the effects of …

Background: Direct oral anticoagulants (DOACs) have widely replaced warfarin for stroke
prevention in nonvalvular atrial fibrillation. Our objective was to compare the safety and …

Aims A Markov model was adapted to assess the real-world cost-effectiveness of
rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral …

Aim: To analyze the frequency and variables related to inappropriate rivaroxaban dosage in
clinical practice and its impact on outcomes after 2 years. Materials & methods …

The treatment of acute coronary syndrome (ACS) in elderly patients continues to be a
challenge because of the characteS. GB ristics of this population and the lack of data and …

Introduction In addition to an increased risk of thromboembolic complications, patients with
atrial fibrillation (AF) are at risk for vascular events. Consequently, complete vascular …